MATER MISERICORDIAE UNIVERSITY HOSPITAL

Their core work

Mater Misericordiae University Hospital is a major teaching hospital in Dublin, Ireland, providing acute care services while engaging in clinical research. Within H2020, their research contributions focus on cardiovascular disease self-management, HIV cure research, and stroke rehabilitation using advanced neurotechnology. They bring clinical expertise and patient access to European research consortia studying neurological and cardiovascular conditions.

What they specialise in

How they've shifted over time

Their early H2020 involvement (2015-2016) centred on chronic disease management — cardiovascular self-management tools and HIV cure research. By 2018, their focus shifted toward neurorehabilitation, specifically stroke recovery using robotics and neurophysiological monitoring (EEG, EMG). This suggests a growing interest in technology-assisted physical rehabilitation and brain-body interface research.

Moving toward technology-driven rehabilitation, combining robotics with neurophysiological measurement — likely to pursue further work in assistive technologies and automated therapy systems.

How they like to work

Mater Misericordiae participates exclusively as a partner, never as coordinator, consistent with a clinical site contributing patients, clinical expertise, and validation capacity to researcher-led consortia. With 19 unique partners across 11 countries from just 3 projects, they join broad European consortia rather than small focused teams. This makes them an accessible clinical partner comfortable working in large, international groups.

Despite only 3 projects, they have collaborated with 19 partners across 11 countries, indicating involvement in large multi-national consortia with broad European reach.

What sets them apart

As a university teaching hospital, they offer a combination that pure research institutes cannot: direct clinical access to patient populations alongside academic research capacity. Their shift toward stroke rehabilitation with robotics and neuroimaging places them at the intersection of clinical medicine and engineering. For consortium builders, they provide the clinical validation and patient recruitment site that technology developers need.

Highlights from their portfolio

• PRO GAIT
  Combines exoskeleton robotics with EEG/EMG brain and muscle monitoring for stroke gait rehabilitation — their most technically specific and keyword-rich project.
• PATHway
  Their largest funded project (EUR 44,454) focused on digital tools for cardiovascular disease behavioural change and self-management.